| Trial | control | p<0.05 | harm | NS |
|---|
| COMET, 2003 | vs metoprolol | all cause death 0.86 [0.78; 0.94] cardiovascular death 0.82 [0.74; 0.91] | | death or HF hospitalisation 0.97 [0.93; 1.01] |
| ANZ-HeFT, 1997 | vs metoprolol | | | NYHA deterioration 1.23 [0.77; 1.97] all cause death 0.77 [0.45; 1.34] cardiovascular death 0.90 [0.49; 1.66] death or HF hospitalisation 0.72 [0.49; 1.06] hospitalisation for heart failure 0.70 [0.43; 1.15] NYHA improvement 0.94 [0.68; 1.28] |
| CARMEN (carvedilol alone), 2004 | vs metoprolol | | | all cause death 0.99 [0.49; 2.03] cardiovascular death 0.92 [0.45; 1.91] hospitalisation for heart failure 0.75 [0.36; 1.53] |
| COPERNICUS, 2002 | vs metoprolol | all cause death 0.67 [0.54; 0.83] death or HF hospitalisation 0.82 [0.74; 0.91] hospitalisation for heart failure 0.67 [0.59; 0.76] | | |
| CAPRICORN, 2001 | vs metoprolol | all cause death 0.78 [0.62; 0.97] cardiovascular death 0.76 [0.60; 0.96] | | death or HF hospitalisation 0.93 [0.83; 1.05] hospitalisation for heart failure 0.86 [0.69; 1.09] |
| Metra, 1994 | vs metoprolol | | | |
| Olsen, 1995 | vs metoprolol | | | |
| Krum, 1995 | vs metoprolol | | | |
| Bristow (MOCHA), 1996 | vs metoprolol | | | |
| Parker, 1996 | vs metoprolol | | | cardiovascular death 0.70 [0.42; 1.17] Sudden death 0.87 [0.42; 1.79] |
| Colucci, 1996 | vs metoprolol | | | |
| Cohn, 1997 | vs metoprolol | | | |
| Carvedilol U.S. Trials (elderly subgroup), 1996 | vs metoprolol | All cause death 0.45 [0.23; 0.86] | | |
| COPERNICUS (elderly subgroup), 2001 | vs metoprolol | All cause death 0.75 [0.57; 0.99] | | |
| Trial | Treatments | Patients | Method |
|---|
| COMET, 2003 | carvedilol (target dose 25 mg twice daily) (n=1511) vs. metoprolol tartrate target dose 50 mg twice daily (n=1518) | chronic heart failure (NYHA II–IV) with a previous admission for a cardiovascular reason and ejection fraction of less than 0·35, and have been treated optimally with diuretics and angiotensinconverting enzyme inhibitors unless not tolerated. | Double blind Parallel groups Sample size: 1511/1518 Primary endpoint: all-cause mortality and the composite endpoint FU duration: 4.83 years |
| ANZ-HeFT, 1997 | carvedilol target dose 25mg twice daily (n=207) vs. placebo (n=208) | chronic stable heart failure, NYHA 1-3 | Double blind Parallel groups Sample size: 207/208 Primary endpoint: Exercise tolerance, EF Morbidity 1 mortality FU duration: 19 mo (range 18-24 mo) |
| CARMEN (carvedilol alone), 2004 | carvedilol (target 25 mg bid) (n=191) vs. enalapril (target 10 mg bid) (n=190) | patients with mild heart failure | ND Sample size: 191/190 Primary endpoint: left ventricular remodelling FU duration: 18 months |
| COPERNICUS, 2002 | carvedilol traget dose of 25 mg twice daily (n=1156) vs. placebo (n=1133) | patients with symptoms of heart failure at rest or on minimal exertion and with an ejection fraction <25% (but not volume-overloaded) | Double blind Parallel groups Sample size: 1156/1133 Primary endpoint: all-cause mortality FU duration: 10.4 months |
| CAPRICORN, 2001 | carvedilol target dose 25mg twice daily (n=975) vs. placebo (n=984) | proven acute myocardial infarction and a left-ventricular ejection fraction of <=40% | Double blind Parallel groups Sample size: 975/984 Primary endpoint: all-cause death or hospitalization FU duration: 1.3 years |
| Metra, 1994 | carvedilol (n=20) vs. placebo (n=20) | NYHA 2-3, IDC | Sample size: 20/20 Primary endpoint: Hemodynamics FU duration: 4 mo |
| Olsen, 1995 | carvedilol (n=36) vs. placebo (n=23) | NYHA 2-4, IDC/CAD | Sample size: 36/23 Primary endpoint: Hemodynamics FU duration: 4 mo |
| Krum, 1995 | carvedilol 25 mg twice daily during 14 weeks (n=33) vs. placebo (n=16) selection of patients tolerating during run-in period 12.5mg twice daily | Patients with advanced heart failure(NYHA 3-4), EF <=0.35 | Sample size: 33/16 Primary endpoint: Hemodynamics FU duration: 3.5 mo |
| Bristow (MOCHA), 1996 | carvedilol (n=261) vs. placebo (n=84) | NYHA 2-4, IDC/CAD | Double blind Parallel groups Sample size: 261/84 Primary endpoint: Exercise tolerance FU duration: 6.5-8 mo |
| Parker, 1996 | carvediloltarget dose 25 mg twice daily (n=696) vs. placebo (n=398) nested dose-ranging protocol (6.25, 12.5, 25 mg twice daily) cocnerning 345 patients (32%) | patients with heart failure and ejection fraction<0.35 | Double blind Parallel groups Sample size: 696/398 Primary endpoint: Exercise tolerance FU duration: 6.5 mo (1 day - 15.1 mo) |
| Colucci, 1996 | carvedilol (n=232) vs. placebo (n=134) | mild symptomatic heart failure; ejection fraction<=0.35; 6-minute walk test of 450-550m; on optimal standard therapy including ACE inhibitors | Double blind Parallel groups Sample size: 232/134 Primary endpoint: progression of heart failure FU duration: 213 days (0.6 years) |
| Cohn, 1997 | carvedilol (n=70) vs. placebo (n=35) | NYHA 3-4, IDC/CAD | Sample size: 70/35 Primary endpoint: Quality of life FU duration: <8 mo |
| Carvedilol U.S. Trials (elderly subgroup), 1996 | Carvedilol (n=554) vs. placebo (n=0) | Patients aged 65 years and older | Sample size: 554/0 Primary endpoint: FU duration: |
| COPERNICUS (elderly subgroup), 2001 | Carvedilol (n=1102) vs. placebo (n=0) | Patients aged 59 years and older | Sample size: 1102/0 Primary endpoint: FU duration: |
